Chimeric antigen receptor-modified T cells derived from defined CD8+ and CD4+ subsets confer superior antitumor reactivity in vivo

by Sommermeyer, Daniel, Hudecek, Michael, Kosasih, Paula L., Gogishvili, Tea, Maloney, David G., Turtle, Cameron J., Riddell, Stanley R.
Published 2015

Safety of targeting ROR1 for cancer immunotherapy with chimeric antigen receptor-modified T cells in a primate model

by Berger, S Carolina, Sommermeyer, Daniel, Hudecek, Michael, Berger, Michael, Balakrishnan, Ashwini, Paskiewicz, Paulina, Kosasih, Paula, Rader, Christoph, Riddell, Stanley
Published 2014